Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS
Acumen Pharmaceuticals — AAIC 2026
12 slides from Acumen Pharmaceuticals's conference presentation, Jul 12, 2026
Slide 1: Bispecific Antibodies that Bind Aβ Oligomers and Transferrin Receptors Show Enhanced Brain Delivery in Cynomolgus Monkeys
Bispecific Antibodies that Bind Aβ Oligomers and Transferrin Receptors Show Enhanced Brain Delivery in Cynomolgus Monkeys Paul Shughrue, PhD VP, Program Lead and Head of Research, Acumen Pharmaceuticals AAIC London, England July 12-15, 2026 1
Slide 2: Disclosures
Disclosures Dr. Shughrue is an employee of Acumen Pharmaceuticals and is a minor shareholder. 2
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and
Slide 4: Concept: Building a Bispecific Antibody
Concept: Building a Bispecific Antibody • The Cargo determines the A species (oligomer, monomer, plaque, pyroglutamate) targeted by the bispecific antibody • Efficacy is dependent on The Cargo The Cargo • The Transporter determines the mechanism used to cross the BBB as well as brain PK Linker • Th
Slide 5: Bispecific EBD Antibodies Retain High Affinity for Transferrin Receptor and Selectivity for Aβ Oligomers
Bispecific Enhanced Brain DeliveryTM (EBDTM)Antibodies Retain the High Affinity for Transferrin Receptor and Selectivity for A Oligomers 0.720 nM 0.853 nM* 3,921 nM 12,728 nM* • The bispecific constructs and the monoclonal antibodies ACU193 and ACU234 exhibit similar binding profiles, each showing
Slide 6: Study Design: Assessment of Bispecific EBD Antibodies in Cynomolgus Monkey
Study Design: Assessment of Bispecific EBDTM Antibodies in Cynomolgus Monkey SC Dosing Study (5 mg/kg) IV Study (below) .083 1 3 6 12 1 2 3 7 14 21 28 35 Dose Antibody Hours Days Collect Plasma Hematology IV Dosing Study (2 mg/kg) Necropsy .083 1 3 6 12 24 Dose Antibody Collect Plasma Hours Collect
Slide 7: Bispecific Antibodies Exhibit Rapid Plasma Uptake after SC Dosing
Bispecific Antibodies Exhibit Rapid Plasma Uptake after SC Dosing First 24 hours shown in B 195.6 hr 79.2 hr 50.8 hr 48.4 hr A B 7
Slide 8: Analysis of Three Brain Regions Showed ~40x Enhancement of Bispecific Antibody Delivery
Analysis of Three Brain Regions Showed 22 - 40x Enhancement of Bispecific Antibody Delivery Over Monoclonal Antibody ACU234 Frontal Cortex Putamen Hippocampus* 60 40x 60 60 35x 27x Conc. (pM) 21x Conc. (pM) Conc. (pM) 40 40 40 22x 21x 22x 16x 15x 20 20 19x 11x 20 14x 0 0 0 ACU234 ACU234 ACU234 ACU40
Slide 9: CSF Concentrations of EBD Antibodies Comparable to ACU234 after IV Administration
CSF Concentrations of EBDTM Antibodies Were Comparable to ACU234 after IV Administration in Cynomolgus Monkeys 250 200 Conc. (pM) 150 100 50 0 ACU451 ACU351 ACU401 ACU234 ACU351 ACU451 ACU234 ACU401 3 Hour 24 Hour 9
Slide 10: No Meaningful Changes in Hematology Endpoints Observed 24 Hours after SC Dosing
No Meaningful Changes in Hematology Endpoints Were Observed 24 Hours after SC Dosing of EBDTM Antibodies in Monkeys Red blood cells Hemoglobin Hematocrit Reticulocyte count 1.5 1.5 1.5 1.5 Reticulocyte count ratio (post/pre) ratio (post/pre) ratio (post/pre) ratio (post/pre) Hemoglobin Hematocrit 1.
Slide 11: Summary
Summary • Bispecific EBDTM constructs of ACU193 or ACU234 with an anti-TfR (scFv or VHH) transporter retain their ability to bind the TfR and to selectively bind A oligomers • Pharmacokinetic studies demonstrated rapid absorption of all bispecific EBDTM antibodies following SC administration • Anal
Slide 12: Thank you!
Thank you! Coauthors: Collaborators: Acumen Pharmaceuticals Cynomolgus Monkey Studies Elizabeth Johnson Shin Nippon Biomedical Laboratories (SNBL), Alex Davis Kagoshima, Japan Ryohei Makino JCR Pharmaceuticals Sho Watanabe Shunsuke Iizuka Sae Niimura Mahiro Kuroda A Binding Fraunhofer IZI, Leipzig,